Loading...
XSHE002437
Market cap731mUSD
Jan 10, Last price  
2.45CNY
1D
4.26%
1Q
15.57%
Jan 2017
-69.98%
IPO
-14.61%
Name

HARBIN GLORIA PHARMACEUTICALS Co Ltd

Chart & Performance

D1W1MN
XSHE:002437 chart
P/E
44.60
P/S
2.04
EPS
0.05
Div Yield, %
0.82%
Shrs. gr., 5y
0.03%
Rev. gr., 5y
-13.69%
Revenues
2.63b
-15.51%
164,113,010275,610,229429,928,954575,448,365546,364,548711,030,3031,307,886,2461,905,823,9912,681,225,3072,983,728,1363,041,883,4535,481,339,8285,053,859,8943,054,949,2663,145,311,7033,107,945,1602,626,039,306
Net income
120m
74,755,721105,950,873130,235,113154,713,039116,848,259164,769,964226,737,497443,770,001664,808,612716,648,314309,675,737125,893,6340400,049,12245,042,0240120,334,186
CFO
274m
+4.80%
52,260,50757,809,411170,815,046112,592,505128,606,944205,889,113453,020,477674,036,849702,047,2041,040,487,154651,795,3251,162,761,434610,365,81712,763,852274,181,021261,615,607274,175,284
Dividend
Jun 28, 20190.012 CNY/sh

Profile

Harbin Gloria Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products primarily in the People's Republic of China. It offers cardiac cerebrovascular medication, skeletal muscle system, vitamins and minerals, urinary system medication, antitumor medication, endocrine medicine, anti-infective drugs, respiratory medication, antihistamine, peptic, and other products. Harbin Gloria Pharmaceuticals Co., Ltd. was founded in 2000 and is based in Harbin, the People's Republic of China.
URL
http://www.gloria.cc/
IPO date
Jun 23, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,626,039
-15.51%
3,107,945
-1.19%
Cost of revenue
2,407,549
2,932,135
Unusual Expense (Income)
NOPBT
218,490
175,810
NOPBT Margin
8.32%
5.66%
Operating Taxes
48,078
19,839
Tax Rate
22.00%
11.28%
NOPAT
170,413
155,971
Net income
120,334
 
Dividends
(43,808)
Dividend yield
0.79%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
675,690
1,454,973
Long-term debt
Deferred revenue
21,433
Other long-term liabilities
17,874
28
Net debt
(366,288)
(241,016)
Cash flow
Cash from operating activities
274,175
261,616
CAPEX
(29,621)
Cash from investing activities
94,380
Cash from financing activities
(889,160)
FCF
225,191
271,809
Balance
Cash
711,275
1,288,307
Long term investments
330,703
407,682
Excess cash
910,676
1,540,592
Stockholders' equity
1,331,711
2,334,627
Invested Capital
1,493,118
1,591,875
ROIC
11.05%
9.53%
ROCE
9.04%
5.59%
EV
Common stock shares outstanding
2,199,894
2,198,123
Price
2.51
-1.18%
2.54
-12.71%
Market cap
5,521,733
-1.10%
5,583,232
-12.71%
EV
5,203,902
5,414,520
EBITDA
326,863
305,855
EV/EBITDA
15.92
17.70
Interest
42,654
68,666
Interest/NOPBT
19.52%
39.06%